BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

  1. Homepage
  2. Medicinal products
  3. Pharmacovigilance
  4. Risk information

Dear Doctor Letter (Rote-Hand-Brief) on Aclasta®: Reports on renal dysfunction and renal failure

2010.03.12

Active substance: zoledronic acid

Additional safety information on reports on renal dysfunction and renal failure with Aclasta®.

Download DHPC / Information letter , Download_VeroeffentlichtAm_EN PDF, 143KB, File is accessible